Literature DB >> 15951828

Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Reiko Takahashi1, Masao Endoh.   

Abstract

Experiments were carried out in canine ventricular trabeculae loaded with aequorin to investigate the effects of levosimendan {(R)-([4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono)-propanedinitrile} on contractile force and Ca(2+) transients in normal and acidotic conditions. The concentration-response curve for the positive inotropic effect (PIE) of levosimendan was bell-shaped, that is, it declined markedly at 10(-4) M after achieving the maximum at 10(-5) M in normal (pH(o)=7.4) and acidotic conditions (pH(o)=6.6). The positive inotropic effect (PIE) of levosimendan up to 10(-5) M was associated with an increase in Ca(2+) transients and a shift of the relationship of Ca(2+) transients and force to the left of that of elevation of [Ca(2+)](o). Levosimendan at 10(-4) M elicited a negative inotropic effect (NIE) in association with a further increase in Ca(2+) transients, and during washout Ca(2+) transients increased further, while the force was abolished before both signals recovered to the control. In acidotic conditions, the relationship of Ca(2+) transients and force during the application of levosimendan in normal conditions was essentially unaltered, whereas the PIE was suppressed due to attenuation of the increase in Ca(2+) transients. In summary, in intact canine ventricular myocardium, levosimendan elicits a dual inotropic effect: at lower concentrations, it induces a PIE by a combination of increases in Ca(2+) transients and Ca(2+) sensitivity, while at higher concentrations it elicits an NIE due to a decrease in Ca(2+) sensitivity. Acidosis inhibits the PIE of levosimendan due to suppression of the increase in Ca(2+) transients in response to the compound.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951828      PMCID: PMC1576237          DOI: 10.1038/sj.bjp.0706292

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Chimera analysis of troponin I domains that influence Ca(2+)-activated myofilament tension in adult cardiac myocytes.

Authors:  M V Westfall; F P Albayya; I I Turner; J M Metzger
Journal:  Circ Res       Date:  2000-03-03       Impact factor: 17.367

Review 2.  Measurement of Ca2+ concentrations in living cells.

Authors:  J R Blinks; W G Wier; P Hess; F G Prendergast
Journal:  Prog Biophys Mol Biol       Date:  1982       Impact factor: 3.667

3.  Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-17       Impact factor: 3.000

4.  Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium.

Authors:  R Takahashi; Y Shimazaki; M Endoh
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

5.  Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium.

Authors:  R Takahashi; M A Talukder; M Endoh
Journal:  Eur J Pharmacol       Date:  2000-07-14       Impact factor: 4.432

6.  Effect of acidosis on Ca2+ uptake and release by sarcoplasmic reticulum of intact rat ventricular myocytes.

Authors:  J T Hulme; C H Orchard
Journal:  Am J Physiol       Date:  1998-09

Review 7.  The therapeutic potential of novel cardiotonic agents.

Authors:  Masao Endoh
Journal:  Expert Opin Investig Drugs       Date:  2003-05       Impact factor: 6.206

Review 8.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.

Authors:  John G F Cleland; Nikolay Nikitin; James McGowan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-01

Review 10.  Mechanisms of action of novel cardiotonic agents.

Authors:  Masao Endoh
Journal:  J Cardiovasc Pharmacol       Date:  2002-09       Impact factor: 3.105

View more
  8 in total

Review 1.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

2.  Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?

Authors:  M Endoh
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

3.  Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.

Authors:  M Louhelainen; E Vahtola; P Kaheinen; H Leskinen; S Merasto; V Kytö; P Finckenberg; W S Colucci; J Levijoki; P Pollesello; H Haikala; E M A Mervaala
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

4.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  Reversal of effects of acidosis on contraction of rat heart myocytes by CGP-48506.

Authors:  Hiroaki Minami; Beata M Wolska; Miroslav O Stojanovic; R John Solaro
Journal:  Front Biosci       Date:  2008-05-01

6.  Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel.

Authors:  E Grossini; C Molinari; P P Caimmi; F Uberti; G Vacca
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

7.  The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium.

Authors:  Øivind Ørstavik; Ornella Manfra; Kjetil Wessel Andressen; Geir Øystein Andersen; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

8.  Does levosimendan act as a Ca2+ sensitizer or PDE3 inhibitor?: Commentary on Orstavik et al., Br J Pharmacol 171: 5169-5181.

Authors:  Masao Endoh
Journal:  Br J Pharmacol       Date:  2015-09       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.